NasdaqGM:AXSMPharmaceuticals
Should Axsome’s New Solriamfetol Phase 3 and AXS-05 Priority Review Prompt Action From AXSM Investors?
Axsome Therapeutics recently dosed the first patient in its CLARITY Phase 3 trial of solriamfetol for major depressive disorder with excessive daytime sleepiness and has also been granted FDA Priority Review for AXS-05 in Alzheimer’s disease agitation, while management engaged investors at several March healthcare conferences.
Together, the new late-stage solriamfetol study and the upcoming AXS-05 regulatory decision highlight how Axsome is steadily broadening its central nervous system...